Drug Trial Radar · NCT07623161
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
324
Planned (sponsor's estimate)
Start
Sep 10, 2026
Primary completion
Dec 7, 2029
Study completion Mar 30, 2034
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo. Other aims are to learn how elritercept improves anemia compared to placebo; to learn if elritercept reduces tiredness, improves symptoms related to MF, and helps participants do physical activities more easily. The study also aims to find out how elritercept affects the bone marrow, the spleen, and whether participants develop antibodies to the study drug. The study will also check how safe elritercept is compared to placebo, and if elritercept stays safe over a long period of time. Participants will receive study treatment for at least 9 months (36 weeks). After this period, participants who received placebo will have the option to switch to elritercept.
Conditions
- Myelofibrosis
- Anemia
Interventions
PlaceboDrug
Elritercept-matching placebo
ElriterceptDrug
Elritercept, SC, injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Who Are Red Blood Cell-Transfusion Independent (RBC-TI) for Any Consecutive Greater Than or Equal to (≥) 12-Week Period During the 36-Week Double-Blinded Treatment PeriodTime frame: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Locations
214 sites in 31 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Not yet recruiting
Los Angeles Cancer Network
Glendale, California · Recruiting
Cancer and Blood Specialty Clinic
Whittier, California · Recruiting
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Not yet recruiting
Advanced Research, LLC
Coral Springs, Florida · Recruiting
Bioresearch Partners
Miami, Florida · Recruiting
AdventHealth - Cancer Institute - Orlando
Orlando, Florida · Not yet recruiting
Florida Clinical Trials Group
Tamarac, Florida · Recruiting
Moffit Cancer Center
Tampa, Florida · Not yet recruiting
Emory University
Atlanta, Georgia · Not yet recruiting
Tufts Medical Center
Boston, Massachusetts · Not yet recruiting
Univ of Michigan
Ann Arbor, Michigan · Withdrawn
Washington University School of Medicine
St Louis, Missouri · Not yet recruiting
St. Vincent Regional Hospital Cancer Centers
Billings, Montana · Recruiting
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico · Not yet recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Not yet recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Not yet recruiting
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Withdrawn
Duke Blood Cancer Center
Durham, North Carolina · Not yet recruiting
Novant Health
Winston-Salem, North Carolina · Not yet recruiting
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina · Withdrawn
Cleveland Clinic
Cleveland, Ohio · Not yet recruiting
Oregon Health and Science University
Portland, Oregon · Not yet recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Not yet recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Not yet recruiting
Allegheny Health Network Cancer Institute - West Penn Hospital Location
Pittsburgh, Pennsylvania · Not yet recruiting
Medical University of South Carolina
Charleston, South Carolina · Not yet recruiting
Baptist Clinical Research Institute
Memphis, Tennessee · Withdrawn
Vanderbilt-Ingram Cancer Center (VICC)-Nashville
Nashville, Tennessee · Not yet recruiting
Next Innovative Clinical Research
Baytown, Texas · Withdrawn
Baylor University Medical Center
Dallas, Texas · Withdrawn
MD Anderson Cancer Center
Houston, Texas · Recruiting
The University of Utah-Huntsman Cancer Institute
Houston, Texas · Not yet recruiting
LUMI Research
Houston, Texas · Recruiting
University of Washington
Seattle, Washington · Not yet recruiting
Hospital Aleman (HA) Deutsches Hospital
Buenos Aires, Argentina · Not yet recruiting
BRCR Global
Córdoba, Argentina · Not yet recruiting
Hospital Universitario Austral
Pilar, Buenos Aires, Argentina · Not yet recruiting
Swiss Medical Center Barrio Parque
Buenos Aires, Ciudad Autonoma de BuenosAires, Argentina · Not yet recruiting
Instituto Medico de la Fundacion Estudios Clinicos
Rosario, Santa Fe Province, Argentina · Not yet recruiting
Showing 40 of 214 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.